An Introduction to Survival Analysis using Stata (Revised Edition).pdf 1: A Comprehensive Guide for

To our knowledge, this is the first analysis to link response to survival to assess the impact of an OBA on both costs and benefits in an analysis of cost-effectiveness of tisagenlecleucel in ALL. The Institute of Clinical and Economic Review in their assessment of effectiveness and value of CAR-T therapies considered an option for an OBA, which was replicated in subsequent publications, although was only considered in relation to the distribution of payments and did not link response status to survival [31,32,33]. Other studies have looked at the impact on the cost-effectiveness of tisagenlecleucel of a response-only payment using clinical remission, although none accounted for any associated change in benefit [54,55,56,57,58].

An Introduction to Survival Analysis using Stata (Revised Edition).pdf 1

Download Zip

2ff7e9595c